Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

87.5%

+0.9% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

2 recruiting4 with results

Enrollment Performance

Analytics

Phase 2
7(63.6%)
Phase 3
4(36.4%)
11Total
Phase 2(7)
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT06128369Phase 3Terminated

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Role: lead

NCT07548632Phase 2Recruiting

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

Role: lead

NCT07623668Phase 3Recruiting

Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

Role: lead

NCT05066997Phase 2Completed

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

Role: lead

NCT06172257Phase 3Completed

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

Role: lead

NCT04762017Phase 2Completed

OCS-05 in Patients With Optic Neuritis

Role: lead

NCT04130802Phase 2Completed

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

Role: lead

NCT05147233Phase 3Completed

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Role: lead

NCT05896670Phase 2Completed

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

Role: lead

NCT05608837Phase 2Active Not Recruiting

Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

Role: collaborator

NCT05343156Phase 2Completed

Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema

Role: lead

All 11 trials loaded